Table 5.
Results of this analysis
| Endpoints | OR with 95% CI | P value | I2 (%) |
|---|---|---|---|
| Any AE | 1.00 [0.81–1.24] | 1.00 | 0 |
| Headache | 0.88 [0.67–1.27] | 0.49 | 0 |
| Nasopharyngitis/URI | 0.95 [0.71–1.27] | 0.75 | 6 |
| Back pain | 0.81 [0.49–1.33] | 0.40 | 0 |
| Dizziness | 0.63 [0.43–0.92] | 0.02 | 0 |
| Diarrhea | 0.83 [0.48–1.44] | 0.52 | 0 |
| Nausea | 0.52 [0.25–1.05] | 0.07 | 0 |
| Weight gain | 2.29 [0.51–10.34] | 0.28 | 80 |
| Peripheral edema | 1.21 [0.56–2.62] | 0.63 | 76 |
Nasopharyngitis and upper respiratory tract infection were combined together during the analysis
Abbreviations: URI upper respiratory infection, AE adverse events, OR odds ratio, CI confidence interval